title: Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study.
abstract: In a multicenter open longitudinal clinical trial where 479 patients suffering from migraine with or without aura were recruited, patients treated at home one to three migraine attacks with their customary treatment, and subsequently, over a 3-month period, one to three migraine attacks with 6 mg sumatriptan sc using an autoinjector. The headache response to customary treatment was 19% at 1 h and 30.5% at 2 h, and was not significantly different when only attacks treated "adequately" according to accepted treatment recommendations were considered: 16% at 1 h and 35% at 2 h. In contrast, 69% and 82% of patients treated with 6 mg sumatriptan sc had mild headache or no headache at 1 and 2 h respectively, regardless of migraine type or duration of symptoms prior to treatment. Other migraine symptoms (nausea, vomiting, photo- and phonophobia) were effectively treated with sumatriptan. Recurrence of migraine was observed in 31% of patients and was well controlled by a second injection of sumatriptan. It is concluded that 6 mg sumatriptan sc, self-administered using an autoinjector, is well tolerated and more effective than most currently used acute treatments for migraine in a population of severely affected patients consulting a neurologist.
authors.affiliation: University Department of Neurology, CHR Citadelle, Liège, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Schoenen
authors.forename: J
authors.initials: J
authors.lastname: Bulcke
authors.forename: J
authors.initials: J
authors.lastname: Caekebeke
authors.forename: I
authors.initials: I
authors.lastname: Dehaene
authors.forename: J
authors.initials: J
authors.lastname: De Keyser
authors.forename: G
authors.initials: G
authors.lastname: Hildebrand
authors.forename: A
authors.initials: A
authors.lastname: Joffroy
authors.forename: P
authors.initials: P
authors.lastname: Laloux
authors.forename: P
authors.initials: P
authors.lastname: Louis
authors.forename: G
authors.initials: G
authors.lastname: Monseu
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000700:Analgesics / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous / Q000295:instrumentation; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy*; D009325:Nausea / Q000188:drug therapy / Q000209:etiology; D010342:Patient Acceptance of Health Care; D010352:Patient Dropouts; D011446:Prospective Studies; D012646:Self Administration; D012678:Sensation Disorders / Q000188:drug therapy / Q000209:etiology; D018170:Sumatriptan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000932:Antiemetics; D018170:Sumatriptan